Literature DB >> 2441634

Detection of human immunodeficiency virus core protein in plasma by enzyme immunoassay. Association of antigenemia with symptomatic disease and T-helper cell depletion.

A E Wittek, M A Phelan, M A Wells, L K Vujcic, J S Epstein, H C Lane, G V Quinnan.   

Abstract

A sensitive enzyme immunoassay was developed for detecting human immunodeficiency virus (HIV) core antigen. Assay sensitivity was 3.67 pmol/L of purified HIV core protein, and 1 or 100 in-vitro infectious units/mL of HIV in purified virus preparations or cell culture supernatants, respectively. Enzyme immunoassay sensitivity exceeded that of reverse transcriptase assay by 1000-fold. Core antigen was detected in whole plasma from 41% of symptomatic subjects and 13% of asymptomatic subjects seropositive for HIV. After plasma fractionation, antigenemia was found in 60% of symptomatic subjects and in 33% of asymptomatic subjects seropositive for HIV. Fifty-seven percent of samples from which HIV could be isolated in lymphocyte culture had detectable quantities of core antigen in plasma. However, at least 87% of samples with measurable antigen in plasma had HIV isolated from lymphocyte cultures. Antigenemia was associated with reduced T-cell number and symptomatic disease, and may be a useful marker for disease progression.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441634     DOI: 10.7326/0003-4819-107-2-286

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

Review 1.  Antigen detection for human immunodeficiency virus.

Authors:  D J Harry; M B Jennings; J Yee; J R Carlson
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

2.  Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.

Authors:  E J Park; G V Quinnan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  Productive human immunodeficiency virus infection levels correlate with AIDS-related manifestations in the patient.

Authors:  D Mathez; D Paul; C de Bélilovsky; Y Sultan; J Deleuze; I Gorin; W Saurin; R Decker; J Leibowitch
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  Antibodies against the major core protein p24 of human immunodeficiency virus: relation to immunological, clinical and prognostic findings.

Authors:  B O Lindhardt; J Gerstoft; B Hofmann; G Pallesen; L Mathiesen; E Dickmeiss; K Ulrich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

5.  Correlation of serum antigen and antibody concentration with clinical features in HIV infection.

Authors:  M Ellaurie; A Rubinstein
Journal:  Arch Dis Child       Date:  1991-02       Impact factor: 3.791

6.  Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay.

Authors:  M B Vasudevachari; N P Salzman; D R Woll; C Mast; K W Uffelman; G Toedter; D Hoefheinz; J A Metcalf; H C Lane
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

7.  Amplification and detection of a single molecule of human immunodeficiency virus RNA.

Authors:  S Nakamura; S Katamine; T Yamamoto; S K Foung; T Kurata; Y Hirabayashi; K Shimada; S Hino; T Miyamoto
Journal:  Virus Genes       Date:  1993-12       Impact factor: 2.332

Review 8.  Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation.

Authors:  P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

9.  Serological response in patients with chronic asymptomatic human immunodeficiency virus infection.

Authors:  B O Lindhardt; K Ulrich; P Kusk; B Hofmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.